Toripalimab
- Generic Name
- Toripalimab
- Brand Names
- Loqtorzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1924598-82-2
- Unique Ingredient Identifier
- 8JXN261VVA
- Background
Toripalimab is under investigation in clinical trial NCT03919383 (Phase II of Lenvatinib Plus Toripalimab for Advanced HCC).
- Indication
⑴用于治疗既往标准治疗失败后的局部进展或转移性黑色素瘤。⑵用于治疗既往接受过二线及以上系统治疗失败的复发/转移性鼻咽癌（NPC）。⑶用于治疗既往接受过治疗的局部进展或转移性尿路上皮癌（UC）。⑷用于食管鳞癌一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Toripalimab Combined With Double Platinum-based Chemotherapy for Initially Unresectable NSCLC
- First Posted Date
- 2019-10-30
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Yongchang Zhang
- Target Recruit Count
- 40
- Registration Number
- NCT04144608
- Locations
- 🇨🇳
Hunan Provincal Tumor Hospital, Changsha, Hunan, China
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2019-10-24
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- TopAlliance Biosciences
- Target Recruit Count
- 499
- Registration Number
- NCT04137900
- Locations
- 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸The Ohio State University Wexner Medical Center The James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States
HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial
- Conditions
- Interventions
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2023-08-15
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 60
- Registration Number
- NCT04135690
- Locations
- 🇨🇳
Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China
High-risk Recurrent or Second Primary HNSCC With PD-1 Antibody Adjuvant After Salvage Surgery(RePASS)
- First Posted Date
- 2019-10-15
- Last Posted Date
- 2019-10-15
- Target Recruit Count
- 41
- Registration Number
- NCT04126460
- Locations
- 🇨🇳
Shanghai ninth people's hospital, Shanghai, Shanghai, China
Toripalimab Combined With Chemotherapy as Neoadjuvant Treatment of Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-10-08
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- Aiping Zhou
- Target Recruit Count
- 30
- Registration Number
- NCT04119622
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences, Beijing, China
Toripalimab Combined With Axitinib as Neoadjuvant Therapy in Patients With Non-metastatic Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-10-08
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04118855
- Locations
- 🇨🇳
Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-09-23
- Last Posted Date
- 2022-03-29
- Target Recruit Count
- 64
- Registration Number
- NCT04099589
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
HAIC Plus Lenvatinib and Toripalimab for Advanced HCC
- Conditions
- Interventions
- First Posted Date
- 2019-08-05
- Last Posted Date
- 2023-06-12
- Lead Sponsor
- Shi Ming
- Target Recruit Count
- 36
- Registration Number
- NCT04044313
- Locations
- 🇨🇳
Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China
Combination of Toripalimab and Chemoradiotherapy in Esophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-07-02
- Last Posted Date
- 2022-08-23
- Lead Sponsor
- Mian XI
- Target Recruit Count
- 42
- Registration Number
- NCT04005170
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guanzhou, Guangdong, China
Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer
- First Posted Date
- 2019-07-02
- Last Posted Date
- 2019-12-26
- Lead Sponsor
- Jianhua Fu
- Target Recruit Count
- 44
- Registration Number
- NCT04006041
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.